Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report - Takeaways - MDSpire

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • By

  • Ruiyue Wu

  • Xi Chen

  • Tong Li

  • Yunmei Zhang

  • Xiaoling Ling

  • May 4, 2026

  • 0 min

Share

  • 1

    Disitamab vedotin (RC-48) is an anti-HER2 antibody-drug conjugate under investigation for HER2-low metastatic breast cancer.

  • 2

    The patient, a 40-year-old woman, showed significant clinical response to RC-48 after failing multiple prior therapies.

  • 3

    HER2 status in the patient changed dynamically, emphasizing the need for repeat biopsies during disease progression.

  • 4

    Following RC-48 treatment, the patient experienced marked regression of chest-wall lesions and partial biochemical improvement.

  • 5

    The case highlights the potential benefit of ADC-based therapy in later-line treatment for HER2-low metastatic breast cancer.

Original Source(s)

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • by Ruiyue Wu, Xi Chen, Tong Li, Yunmei Zhang, Xiaoling Ling

  • May 4, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases